Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Skylark Bio
AddedFeb 15, 2024
UpdatedJun 18, 2026
Skylark Bio

Skylark Bio

Series B

Skylark Bio, a Cambridge-based biotech firm, pioneers gene therapies for hearing loss.

HQ
Cambridge, MA, US
Founded
2021
Overview
Compare
Fundraising
Employees
Website

Skylark Bio, founded in 2021 and based in Cambridge, Massachusetts, is a biotechnology company dedicated to developing gene therapies for treating hearing loss. The company's core mission is to create a world where everyone can experience life in all its sensory dimensions. Skylark Bio focuses on innovative gene therapy solutions to address the genetic causes of hearing impairment, aiming to enhance or restore natural communication abilities.

Notable affiliated individuals include leading scientists and advisors in the field of gene therapy and biotechnology. Skylark Bio has attracted significant interest from investors due to its pioneering approach and potential impact on sensory health. Key achievements include advancing preclinical studies and securing funding to accelerate their research. Skylark Bio's work promises to make a profound impact on the quality of life for individuals with hearing impairments.

Skylark Bio - Quick Facts

When was Skylark Bio founded?

Skylark Bio was founded in 2021.

Where is Skylark Bio's headquarters located?

Skylark Bio's headquarters is located in Cambridge, MA, US.

When was Skylark Bio's last funding round?

Skylark Bio's most recent funding round was for $22.9M (USD) in August 2022.

How much has Skylark Bio raised to-date?

As of Aug 16, 2022, Skylark Bio has raised a total of $22.9M (USD).

How many employees does Skylark Bio have?

Skylark Bio has 6 employees as of Feb 5, 2024.

Skylark Bio - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Gene Therapy
Tags
  • Biotech
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 15 more industry codes
NAICS
  • 513200Software Publishers
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 510000Information
  • 620000Health Care and Social Assistance
  • 513000Publishing Industries
  • 541700Scientific Research and Development Services
  • 513210Software Publishers
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 7372Prepackaged Software
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research